TDC
BOLD

Thompson Davis & Co’s Audentes Therapeutics, Inc BOLD Stock Holding History

Thompson Davis & Co’s Portfolio BOLD Stock Details BOLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-125
Closed -$4K – 786
2018
Q1 		$4K Hold
125
– – 0.01% 531
2017
Q4 		$4K Sell
125
-125
-50% -$3.43K 0.01% 562
2017
Q3 		$7K Buy
+250
New +$5.43K 0.01% 795

Other funds holding BOLD

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Thompson Davis & Co's BOLD Position: Q2 2018 in Review

Thompson Davis & Co sold out of Audentes Therapeutics, Inc (BOLD) in Q2 2018, closing a stake of 125 shares — an estimated $4K sold.

Thompson Davis & Co first reported a position in BOLD in Q3 2017 and held it in 3 quarters. The position peaked at $7K in Q3 2017. 123 funds tracked by Wall St. Rank hold BOLD as of Q2 2018.

  • Thompson Davis & Co reported no remaining Audentes Therapeutics, Inc position as of Q2 2018 after selling out during the quarter.
  • Thompson Davis & Co sold 125 Audentes Therapeutics, Inc shares in Q2 2018, an estimated $4K.
  • Thompson Davis & Co first reported a position in Audentes Therapeutics, Inc in Q3 2017 and held it in 3 quarters.
  • Thompson Davis & Co's Audentes Therapeutics, Inc position peaked at $7K in Q3 2017.
  • 123 funds tracked by Wall St. Rank held Audentes Therapeutics, Inc as of Q2 2018.

Based on Thompson Davis & Co's 13F filing for Q2 2018, filed 3 Aug 2018.